Targeted Genetics Corporation (Nasdaq:TGEND) reported preliminary efficacy data from its ongoing Phase I/II trial of tgAAC94 in patients with...
Targeted Genetics Corporation (Nasdaq:TGEND) reported new data from studies designed to enhance the company's ability to develop novel therapeutic...
Company-Sponsored Research Featured as One Of "Top Five Abstracts" at the Presidential Symposium at the American Society of Gene Therapy...
Targeted Genetics Corporation (Nasdaq:TGEND) is reporting new developments in its portfolio of AAV manufacturing capabilities at the American...
Preliminary Data Show Positive Trends toward Sustained Improvement in Signs and Symptoms of Disease ? Targeted Genetics Corporation...
Presentations Include Preliminary Data from an Ongoing Phase I/II Trial of tgAAC94 in Patients with Inflammatory Arthritis and 13 Additional...
Targeted Genetics Corporation (Nasdaq:TGEN) today announced that it has effected a one-for-ten reverse split of its common stock. The reverse...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.